Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock Holdings Raised by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNXFree Report) by 9.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 655,418 shares of the company’s stock after purchasing an additional 58,369 shares during the period. Charles Schwab Investment Management Inc. owned about 0.82% of Crinetics Pharmaceuticals worth $33,492,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of CRNX. Comerica Bank bought a new position in Crinetics Pharmaceuticals during the 1st quarter worth approximately $33,000. Quest Partners LLC acquired a new position in Crinetics Pharmaceuticals in the second quarter worth $42,000. Values First Advisors Inc. bought a new stake in Crinetics Pharmaceuticals during the third quarter valued at $84,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Crinetics Pharmaceuticals during the third quarter worth $91,000. Finally, KBC Group NV lifted its position in shares of Crinetics Pharmaceuticals by 22.8% in the 3rd quarter. KBC Group NV now owns 2,193 shares of the company’s stock worth $112,000 after buying an additional 407 shares during the last quarter. 98.51% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently weighed in on CRNX. Oppenheimer reiterated an “outperform” rating and set a $73.00 price objective (down previously from $74.00) on shares of Crinetics Pharmaceuticals in a research note on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating and set a $90.00 price objective on shares of Crinetics Pharmaceuticals in a research report on Monday, September 16th. HC Wainwright increased their target price on Crinetics Pharmaceuticals from $69.00 to $81.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. JMP Securities reissued a “market outperform” rating and set a $80.00 price target on shares of Crinetics Pharmaceuticals in a report on Friday, September 27th. Finally, Citigroup increased their price objective on shares of Crinetics Pharmaceuticals from $70.00 to $74.00 and gave the stock a “buy” rating in a report on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $70.18.

Get Our Latest Stock Analysis on CRNX

Insider Buying and Selling at Crinetics Pharmaceuticals

In other news, insider Dana Pizzuti sold 14,375 shares of the firm’s stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $54.63, for a total transaction of $785,306.25. Following the completion of the sale, the insider now directly owns 28,507 shares of the company’s stock, valued at $1,557,337.41. This trade represents a 33.52 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Stephen F. Betz sold 1,035 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $51.50, for a total value of $53,302.50. Following the sale, the insider now directly owns 68,576 shares in the company, valued at $3,531,664. This trade represents a 1.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 40,911 shares of company stock valued at $2,144,675. 6.00% of the stock is owned by insiders.

Crinetics Pharmaceuticals Trading Down 1.4 %

NASDAQ CRNX opened at $56.59 on Wednesday. Crinetics Pharmaceuticals, Inc. has a 12 month low of $32.22 and a 12 month high of $62.53. The company’s 50 day simple moving average is $55.87 and its 200 day simple moving average is $51.92.

Crinetics Pharmaceuticals (NASDAQ:CRNXGet Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.05). During the same period in the prior year, the company earned ($1.01) earnings per share. As a group, analysts predict that Crinetics Pharmaceuticals, Inc. will post -3.75 EPS for the current fiscal year.

Crinetics Pharmaceuticals Company Profile

(Free Report)

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.

Featured Stories

Want to see what other hedge funds are holding CRNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNXFree Report).

Institutional Ownership by Quarter for Crinetics Pharmaceuticals (NASDAQ:CRNX)

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.